BCM Advisors LLC
09/19/2024 | Press release | Distributed by Public on 09/19/2024 14:56
Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/19/2024 | Press release | Distributed by Public on 09/19/2024 14:56
Please select the service you want to use:
Smartlinks | BCM Advisors LLC | Finance | Security Markets | Security Markets | Company News | Shareholders | Shareholder Meeting | Proxy Statements | Financial Services | Investment Funds | Investment Services | Private Companies | Investment Management Companies
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact